Value of immunohistochemical-determined oestrogen receptor status and proliferative activity in breast cancer: A retrospective study including patients treated by endocrine therapy at the time of recurrence

Breast

Volumn 5, Issue 3, 1996, Pages 127-134

  Jensen, V ^a,b   Andersen, J ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FORMALDEHYDE; HORMONE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 0030057069     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90056-9     Document Type: Article

References (30)

1. Andersen J, Poulsen H S. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989; 64: 1901-1908.
2. Andersen J, Thorpe S M, King W J et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid binding assays. Eur J Cancer 1990; 26: 442-449.
3. Andersen J, Thorpe S M, Rose C et al. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. Acta Oncol 1991; 30: 685-690.
4. Campell F C, Blarney R W, Elston C W et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981; 12: 1317-1319.
5. Bezwoda W R, Esser J D, Dansey R, Kessel I, Lange M. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 1991; 69: 867-872.
6. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
7. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody KI-67. J Immunol 1884; 133: 1710-1715.
8. Key G, Becker M H G, Baron et al. New Ki-67-equivalent murine monoclonal antibodies (MIB-1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993; 68: 629-636.
9. Cattoretti G, Becker M H G, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
10. Shi S, Key M E, Kalra K L. Antigen retrieval in formalin-fixed, praffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.
11. Gerdes J, Pickartz H, Brotherton J et al. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol 1987; 129: 486-492.
12. Elston C W, Ellis I O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-410.
13. Gundersen H J G. Notes on the estimation of the numerical density of arbitrary profiles; the edge effect. J Microsc 1977; 111: 219-223.
14. Dao T L, Nemoto T. Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast. Cancer 1980; 46: 2779-2782.
15. Barnard N J, Hall P A, Lemoine N R, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987; 152: 287-295.
16. Gasparini G, Dal Fior S, Pozza F, Bevilacqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histological factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat 1989; 14: 329-336.
17. Weikel W, Beck T, Mitze M, Knapstein P G. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991; 18: 149-154.
18. Veronese S M, Gampacorta M. Detection of Li-67 proliferation rate in breast cancer. Correlation with clinical and pathological features. Am J Clin Pathol 1991; 95: 30-34.
19. Gerdes J, Lelle R J, Pickartz H et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 1986; 39: 977-980.
20. Aaltoma S. Lipponen P, Eskelinen M et al. Hormone receptors as prognostic factors in female breast cancer. Ann Med 1991; 23: 643-648.
21. Williams M R, Todd J H, Ellis I O et al. Oestrogen receptors in primary and advanced breast cancer: an 8-year review of 704 cases. Br J Cancer 1987; 55: 67-73.
22. Nomura Y, Miura S, Koyama H et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 1992; 69: 153-164.
23. Blarney R W, Bishop H M, Blake J R S et al. Relationship between primary breast tumor receptor status and patient survival. Cancer 1980; 46: 2765-2769.
24. Weikel W, Beck T, Mitze M, Knapstein P G. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991; 18: 149-154.
25. Wintzer H O, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991; 67: 421-428.
26. Veronese S M, Campacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71: 3926-3931.
27. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Sørensen F B. The prognostic value of oncogenic antigen 519 (0A-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol in press.
28. Andersen J, Poulsen H S. Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. Acta Oncol 1988; 27: 761-765.
29. Mori T, Morimoto T, Komaki K, Monden Y. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 1991; 68: 532-537.
30. Kamby C, Rasmussen B B, Kristensen B. Oestrogen-receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 252-257.